X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
phenylthiohydantoin - analogs & derivatives (702) 702
humans (651) 651
male (624) 624
index medicus (503) 503
prostate cancer (358) 358
prostatic neoplasms, castration-resistant - drug therapy (340) 340
phenylthiohydantoin - therapeutic use (329) 329
enzalutamide (254) 254
oncology (240) 240
phenylthiohydantoin - pharmacology (205) 205
antineoplastic agents - therapeutic use (184) 184
prostatic neoplasms - drug therapy (183) 183
prostatic neoplasms, castration-resistant - pathology (177) 177
animals (176) 176
chemotherapy (165) 165
receptors, androgen - metabolism (163) 163
abiraterone (162) 162
urology & nephrology (162) 162
aged (160) 160
cell line, tumor (153) 153
metastasis (142) 142
androgen receptor (141) 141
middle aged (141) 141
treatment outcome (139) 139
increased survival (137) 137
receptors, androgen - genetics (135) 135
cancer (133) 133
abiraterone acetate (131) 131
docetaxel (126) 126
drug resistance, neoplasm (110) 110
phenylthiohydantoin - administration & dosage (106) 106
prostatic neoplasms - pathology (102) 102
care and treatment (98) 98
androgen antagonists - therapeutic use (97) 97
androgens (97) 97
castration (97) 97
mice (96) 96
prostatic neoplasms, castration-resistant - metabolism (96) 96
aged, 80 and over (94) 94
taxoids - therapeutic use (94) 94
androstenes - therapeutic use (87) 87
phenylthiohydantoin - adverse effects (85) 85
urology (85) 85
antineoplastic agents - pharmacology (81) 81
prostate (81) 81
disease-free survival (79) 79
article (78) 78
neoplasm metastasis (75) 75
antitumor-activity (72) 72
disease progression (70) 70
therapy (70) 70
antiandrogen (68) 68
prostatic neoplasms - metabolism (68) 68
survival (68) 68
androgen receptor antagonists - therapeutic use (66) 66
prostate-specific antigen - blood (65) 65
signal transduction - drug effects (65) 65
expression (64) 64
prostatic neoplasms, castration-resistant - genetics (64) 64
cell proliferation - drug effects (62) 62
prostatic neoplasms - genetics (62) 62
antineoplastic combined chemotherapy protocols - therapeutic use (61) 61
castration-resistant prostate cancer (61) 61
progression (61) 61
androgen antagonists - pharmacology (58) 58
prednisone (58) 58
retrospective studies (58) 58
androstenes (56) 56
prostatic neoplasms, castration-resistant - mortality (56) 56
research (56) 56
analysis (55) 55
double-blind (55) 55
xenograft model antitumor assays (55) 55
drug therapy (54) 54
androstenols - therapeutic use (53) 53
drug resistance, neoplasm - genetics (53) 53
mitoxantrone (52) 52
pharmacology & pharmacy (52) 52
prostatic neoplasms, castration-resistant - blood (52) 52
antineoplastic agents, hormonal - therapeutic use (50) 50
hematology, oncology and palliative medicine (49) 49
survival analysis (48) 48
cancer therapies (47) 47
cell biology (47) 47
biochemistry & molecular biology (46) 46
endocrinology & metabolism (46) 46
amino acid sequence (45) 45
men (45) 45
resistance (45) 45
androgen receptor antagonists - pharmacology (44) 44
metastases (44) 44
cells (43) 43
prognosis (43) 43
cabazitaxel (42) 42
mdv3100 (42) 42
mutation (42) 42
drug resistance, neoplasm - drug effects (41) 41
gene expression regulation, neoplastic - drug effects (41) 41
medical research (41) 41
abiraterone acetate - therapeutic use (40) 40
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (705) 705
German (12) 12
French (11) 11
Japanese (7) 7
Hungarian (2) 2
Italian (2) 2
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Russian (1) 1
Spanish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Tumori, ISSN 0300-8916, 2014, Volume 100, Issue 3, pp. 249 - 253
Aims and background. Castration-resistant prostate cancer is a recent biological behavior where disease can elude androgen deprivation therapy (ADT). Several... 
Castration-resistantprostate cancer | Somatostatin analogs | Androgen deprivation therapy | Neuroendocrine differentiation | androgen deprivation therapy | CELLS | ANDROGEN-RECEPTOR GENE | MITOXANTRONE | somatostatin analogs | castration-resistant prostate cancer | HORMONAL TREATMENT | DOCETAXEL | PREDNISONE | ONCOLOGY | IN-VIVO | GROWTH | CARCINOMA | neuroendocrine differentiation | Humans | Somatostatin - administration & dosage | Male | Gonadotropin-Releasing Hormone - analogs & derivatives | Peptides, Cyclic - administration & dosage | Neoplasm Grading | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Octreotide - administration & dosage | Somatostatin - analogs & derivatives | Drug Administration Schedule | Prostatic Neoplasms, Castration-Resistant - blood | Adenocarcinoma - blood | Antineoplastic Agents, Hormonal - administration & dosage | Androstenes | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Octreotide - therapeutic use | Adenocarcinoma - drug therapy | Disease Progression | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Biomarkers, Tumor - blood | Phenylthiohydantoin - administration & dosage | Androgen Antagonists - therapeutic use | Peptides, Cyclic - therapeutic use | Aged | Androstenols - administration & dosage | Somatostatin - therapeutic use | Chromogranin A - blood
Journal Article
Journal Article
Genome Biology, ISSN 1474-7596, 01/2016, Volume 17, Issue 1, p. 10
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 11, pp. 1028 - 1038
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 5, pp. 424 - 433
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2012, Volume 367, Issue 13, pp. 1187 - 1197
Journal Article
Journal Article
European Urology, ISSN 0302-2838, 2016, Volume 71, Issue 4, pp. 630 - 642
Journal Article